<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002003</url>
  </required_header>
  <id_info>
    <org_study_id>055A</org_study_id>
    <secondary_id>3-100</secondary_id>
    <nct_id>NCT00002003</nct_id>
  </id_info>
  <brief_title>Phase II Study of Novantrone(R) (Mitoxantrone) and Etoposide in Patients With HIV Associated Large Cell and Immunoblastic Lymphomas</brief_title>
  <official_title>Phase II Study of Novantrone(R) (Mitoxantrone) and Etoposide in Patients With HIV Associated Large Cell and Immunoblastic Lymphomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lederle Laboratories</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To determine the efficacy and toxicity of the combination of mitoxantrone hydrochloride (
      Novantrone ) and etoposide in the treatment of patients with HIV associated lymphomas.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Lymphoma, Non-Hodgkin</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitoxantrone hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        Patients must have the following:

          -  Positive HIV antibody, positive HIV culture or antigen capture, or prior diagnosis of
             AIDS by the CDC criteria.

          -  Diagnosis by pathological examination of large cell or immunoblastic lymphoma within
             measurable or evaluable disease.

          -  Pneumocystis carinii pneumonia (PCP) prophylaxis during the course of the study.

          -  Signed written informed consent.

        Exclusion Criteria

        Co-existing Condition:

        Patients with the following conditions or symptoms are excluded:

          -  Acute intercurrent opportunistic infection, such as Pneumocystis carinii pneumonia
             (PCP) diagnosed within 3 weeks.

          -  Stage IE Central Nervous System lymphomas.

        Patients with the following are excluded:

          -  More than one previous treatment for lymphoma.

          -  Acute intercurrent opportunistic infection, such as Pneumocystis carinii pneumonia
             (PCP) diagnosed within 3 weeks.

          -  Conditions that preclude obtaining an informed consent.

          -  Not accessible for scheduled treatment visits or follow-up.

          -  Stage IE Central Nervous System (CNS) lymphomas.

        Prior Medication:

        Excluded within 2 weeks of study entry:

          -  Zidovudine.

          -  Excluded:

          -  Doxorubicin dosing = or &gt; 300 mg/m2.

        Prior Treatment:

        Excluded:

          -  Received more than one previous treatment regimen for lymphoma.

        Required:

          -  Prophylactic treatment for Pneumocystis carinii pneumonia (PCP) prophylaxis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UMDNJ - New Jersy Med School</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>071032714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Univ Med Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Luke's - Roosevelt Hosp Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 1992</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Mitoxantrone</keyword>
  <keyword>Lymphoma, Large-Cell</keyword>
  <keyword>Etoposide</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Plasmablastic Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Large-Cell, Immunoblastic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Mitoxantrone</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

